These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 10815158)
1. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Hrach CJ; Johnson MW; Hassan AS; Lei B; Sieving PA; Elner VM Arch Ophthalmol; 2000 May; 118(5):659-63. PubMed ID: 10815158 [TBL] [Abstract][Full Text] [Related]
2. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Johnson MW; Olsen KR; Hernandez E; Irvine WD; Johnson RN Arch Ophthalmol; 1990 Feb; 108(2):259-63. PubMed ID: 2105712 [TBL] [Abstract][Full Text] [Related]
3. Retinal toxicity of intravitreal tenecteplase in the rabbit. Rowley SA; Vijayasekaran S; Yu PK; McAllister IL; Yu DY Br J Ophthalmol; 2004 Apr; 88(4):573-8. PubMed ID: 15031179 [TBL] [Abstract][Full Text] [Related]
4. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Chen SN; Yang TC; Ho CL; Kuo YH; Yip Y; Chao AN Ophthalmology; 2003 Apr; 110(4):704-8. PubMed ID: 12689889 [TBL] [Abstract][Full Text] [Related]
5. Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model. Yamamoto T; Kamei M; Kunavisarut P; Suzuki M; Tano Y Graefes Arch Clin Exp Ophthalmol; 2008 Apr; 246(4):509-14. PubMed ID: 17960414 [TBL] [Abstract][Full Text] [Related]
6. Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Irvine WD; Johnson MW; Hernandez E; Olsen KR Arch Ophthalmol; 1991 May; 109(5):718-22. PubMed ID: 1902663 [TBL] [Abstract][Full Text] [Related]
7. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Coll GE; Sparrow JR; Marinovic A; Chang S Retina; 1995; 15(4):319-26. PubMed ID: 8545578 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal toxicity of garenoxacin. Esfahani MR; Kazi AA; Peyman GA; Dellacroce JT; Aydin E Retina; 2006 Feb; 26(2):182-6. PubMed ID: 16467675 [TBL] [Abstract][Full Text] [Related]
9. Toxicity of the photosensitizer NPe6 following intravitreal injection. El-Dessouky ES; Moshfeghi AA; Peyman GA; Yoneya S; Mori K; Kazi AA; Moshfeghi DM Ophthalmic Surg Lasers; 2001; 32(4):316-21. PubMed ID: 11475398 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal voriconazole: an electroretinographic and histopathologic study. Gao H; Pennesi ME; Shah K; Qiao X; Hariprasad SM; Mieler WF; Wu SM; Holz ER Arch Ophthalmol; 2004 Nov; 122(11):1687-92. PubMed ID: 15534131 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. Benner JD; Morse LS; Toth CA; Landers MB; Hjelmeland LM Arch Ophthalmol; 1991 Dec; 109(12):1731-6. PubMed ID: 1841586 [TBL] [Abstract][Full Text] [Related]
15. Resolution of experimental intravitreal fibrin by tissue plasminogen activator. Min WK; Kim YB Korean J Ophthalmol; 1990 Dec; 4(2):58-65. PubMed ID: 2128708 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment. Unal M; Peyman GA Retina; 2000; 20(1):69-75. PubMed ID: 10696751 [TBL] [Abstract][Full Text] [Related]
17. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Kamei M; Misono K; Lewis H Am J Ophthalmol; 1999 Dec; 128(6):739-46. PubMed ID: 10612511 [TBL] [Abstract][Full Text] [Related]
18. [Retinal toxicity of intravitreal doxycycline. A pilot study]. Aydin E; Kazi AA; Peyman GA; Esfahani MR; Muñoz-Morales A; Kivilcim M; Caro-Magdaleno M Arch Soc Esp Oftalmol; 2007 Apr; 82(4):223-8. PubMed ID: 17443427 [TBL] [Abstract][Full Text] [Related]